VTVT — vTv Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1641489 ·
Last close
$30.08
Market Cap
$118.93M
52W High
$44.00
52W Low
$19.50
ADV30
41,858
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -13,930,000 | -13,054,000 | 87,593,000 | 86,643,000 | 8,961,000 |
| Mar 2026 | 36,839,000 | — | 23,263,000 | 24,134,000 | 98,813,000 | 98,086,000 | 8,854,000 |
| Dec 2025 | 0 | — | -7,885,000 | -7,138,000 | 89,899,000 | 88,932,000 | 25,462,000 |
| Sep 2025 | 0 | — | -10,699,000 | -8,698,000 | 99,494,000 | 98,504,000 | 28,951,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,762,000
Investing CF
—
Financing CF
$77,441,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.06
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-315,612,000
Inventory
—
Receivables
$62,000
ST Investments
—
EBIT TTM
$-8,144,000
Pretax Income TTM
$-6,403,000
Interest Exp TTM
$6,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,839,000
EBITDA
$-9,245,000
Free Cash Flow
$674,375
Enterprise Value
$310,569,920
Total Cash
$86,643,000
Total Debt
$0
Shares Out
3,953,928
Trailing EPS
$-0.75
Book Value
$6.34
ROE
-15.8%
ROA
-10.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -32,808,000 | -26,974,000 | 89,899,000 | 25,462,000 | 64,437,000 | -25,255,000 |
| Dec 2024 | 1,017,000 | -24,180,000 | -18,462,000 | 38,266,000 | 23,965,000 | 12,199,000 | -25,307,000 |
| Dec 2023 | 0 | -25,502,000 | -20,250,000 | 11,018,000 | 29,567,000 | -24,680,000 | -19,081,000 |
| Dec 2022 | 2,018,000 | -22,540,000 | -19,164,000 | 33,238,000 | 27,399,000 | -10,740,000 | -16,022,000 |
TTM Snapshot
Revenues TTM
$36,839,000
NetIncome TTM
$2,252,000
OpCashFlow TTM
—
Assets (Latest)
$98,813,000
Forward EPS
$-4.29
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | $118.18M | $1.99 | — |
| COYA | Coya Therapeutics, Inc. | $117.05M | $4.99 | — |
| QUCY | Quantum Cyber N.V. | $116.85M | $1.39 | — |
| HURA | TuHURA Biosciences, Inc./NV | $122.99M | $1.93 | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $124.86M | $7.28 | — |
News headlines (Yahoo Finance, 1h cache)
vTv Therapeutics stock jumps on FDA orphan drug status
2026-10-08 13:43 · Yahoo
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
2026-10-07 20:01 · Yahoo
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
2026-10-06 12:00 · Yahoo
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
2026-10-05 12:00 · Yahoo
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-19 20:05 · Yahoo
vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next
2026-05-17 13:26 · Yahoo
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable
2026-05-15 12:55 · Yahoo
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 20:01 · Yahoo
vTv Therapeutics to Participate in Upcoming May Investor Conferences
2026-05-07 12:00 · Yahoo
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet
2026-04-02 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.